Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
ABT-888 and Temozolomide for Liver Cancer
NCT01205828 · Georgetown University · PHASE2 · terminated · last registry update 2025-02-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of efficacy” | – | Registry record, Georgetown University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PARP1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-12Results posted on the registry: University of Michigan Rogel Cancer Center, Pembrolizumab + Pemetrexed (NCT03559049)
- 2026-02-12Also stopped (terminated): University of Michigan Rogel Cancer Center, Pembrolizumab + Pemetrexed (NCT03559049)
- 2026-02-09Also stopped (terminated): Jiangsu Simcere Pharmaceutical Co., Ltd., SIM0501 Tablets + SIM0501 Tablets (NCT06331559)
- 2026-01-22Results posted on the registry: Janssen Research & Development, LLC, Niraparib+ Abiraterone acetate fixed dose combination (FDC) + Abiraterone acetate (AA) (NCT04497844)
- 2026-01-22Results posted on the registry: University of Alabama at Birmingham, Combination of Veliparib + Lapatinib (NCT02158507)
- 2026-01-21Results posted on the registry: GlaxoSmithKline, Niraparib (Tablet for oral suspension) + Dostarlimab (NCT04544995)
- 2026-01-21Also stopped (terminated): GlaxoSmithKline, Niraparib (Tablet for oral suspension) + Dostarlimab (NCT04544995)
- 2026-01-16Results posted on the registry: Repare Therapeutics, RP-3467 at assigned dose and schedule + Olaparib 200-300 mg BID, daily (NCT06560632)
- 2026-01-16Also stopped (terminated): Repare Therapeutics, RP-3467 at assigned dose and schedule + Olaparib 200-300 mg BID, daily (NCT06560632)
- 2025-12-31Results posted on the registry: Tesaro, Inc., Niraparib + Dostarlimab (TSR-042) (NCT03602859)
- 2025-12-23Results posted on the registry: AstraZeneca, olaparib + durvalumab (NCT04269200)
- 2025-12-22Also stopped (terminated): Thomas Jefferson University, Olaparib (NCT03955640)
- 2025-12-19Results posted on the registry: AstraZeneca, olaparib + enzalutamide (NCT05457257)
- 2025-12-08Results posted on the registry: Memorial Sloan Kettering Cancer Center, Rucaparib (NCT03542175)
- 2025-12-01Also stopped (terminated): Gustave Roussy, Cancer Campus, Grand Paris, Dostarlimab + Niraparib (NCT04779151)
- 2025-12-01Also stopped (withdrawn): Gustave Roussy, Cancer Campus, Grand Paris, Pembrolizumab + Pembrolizumab and Olaparib (NCT06116578)
- 2025-12-01Also stopped (terminated): Gustave Roussy, Cancer Campus, Grand Paris, Atezolizumab + Rucaparib (NCT04276376)
- 2025-11-26Also stopped (terminated): Tesaro, Inc., Niraparib + Carboplatin (NCT06964165)
- 2025-11-21Results posted on the registry: Rush University Medical Center, Folic Acid Tablet (NCT04024254)
- 2025-11-21Results posted on the registry: Gordon Mills, MD, PhD, Capivasertib + Ceralasertib (NCT03801369)
- 2025-11-06Results posted on the registry: Georgetown University, ABT-888 + mFOLFOX-6 (NCT01489865)
- 2025-11-06Also stopped (terminated): Nuvation Bio Inc., NUV-868 + Olaparib (NCT05252390)
- 2025-10-30Results posted on the registry: Repare Therapeutics, RP-3500 (camonsertib) (NCT04972110)
- 2025-10-30Also stopped (terminated): Repare Therapeutics, RP-3500 (camonsertib) (NCT04972110)
- 2025-10-29Results posted on the registry: Tempus AI, Niraparib (NCT05169437)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision